Dfn-15
Benign Prostatic Hyperplasia
Buddhist Tzu Chi General HospitalPhase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 41/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Benign Prostatic Hyperplasia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DINITROGEN MONOXIDE Beth Israel Deaconess Medical Center | Phase 4 | BB |
AVOLVE Turku University Hospital | Phase 4 | BB |
TESTOSTERONE UNDECYLATE University of Florence | Phase 4 | BB |
Oxygen Beth Israel Deaconess Medical Center | Phase 4 | BB |
DICLOFENAC Taha Uçar | Phase 4 | BB |
View all 17 →
Same molecule, other indications
Dfn-15 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →